FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3	3235-028								

87 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WEISER MICHAEL				<u> 1</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol  MANHATTAN PHARMACEUTICALS  INC [ MHTT.OB ]								**				0% Owner
(Last) 130 EAS	(F T 75TH ST	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/28/2004								Office below)	(give title	Other (spe below)		pecify
(Street) NEW Y	ORK N	Y	10023	4	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Lir	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		1.0001												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transacti ate Ionth/Day	Execution Date,		Code (Instr.			Benefic	es ally Following	6. Owners Form: Dire (D) or Indi (I) (Instr. 4	ect E	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	v /	Amount	mount (A) or (D)		Transac	Transaction(s) (Instr. 3 and 4)		"	1150.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  3. Transaction Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr.		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	Ow For Dire or I (I) (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Share	s	(Instr. 4)	(3)		
Warrant	\$1.21	01/27/2004		J <sup>(1)</sup>		103,655		01/27/2004	01/2	27/2009	Common	103,65	5 \$0.01	128,655	5	D	
Option	\$1.65	01/28/2004		A		75,000		(2)	01/2	27/2014	Common	25,000	\$0	128,655	5	D	

## **Explanation of Responses:**

1. In connection with a private placement offering by the Issuer, Paramount Capital, Inc. ("Paramount"), an NASD member broker dealer acted as placement agent. As partial consideration for such services, the Issuer issued to Paramount Unit Purchase Options to acquire 10% of the number of shares of Common Stock sold by the Issuer in such private placement at an exercise price equal to 110% of the purchase price. Dr. Weiser, an employee of Paramount, was issued warrants described in Table II above.

2. 25,000 have vested. 25,000 vest if at all, on 1/28/05 and 1/28/06, respectively.

/s/ Michael Weiser

01/30/2004

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.